Company profile

Future of Amgen

#
Rank
81
| Quantumrun Global 1000

Amgen Inc. was formerly known as Applied Molecular Genetics Inc. It is a US biopharmaceutical company operating internationally. Its headquarters is in Thousand Oaks, California. It’s the largest independent biotechnology firm in the world which is located in Conejo Valley, Amgen.

Home Country:
Sector:
Industry:
Pharmaceuticals
Website:
Founded:
1980
Global employee count:
19200
Domestic employee count:
Number of domestic locations:
9

Financial Health

Revenue:
$22991000000 USD
3y average revenue:
$21572000000 USD
Operating expenses:
$8902000000 USD
3y average expenses:
$9105666667 USD
Funds in reserve:
$3241000000 USD
Market country
Revenue from country
0.80

Asset Performance

  1. Product/Service/Dept. name
    Enbrel
    Product/Service revenue
    5430000000
  2. Product/Service/Dept. name
    Neulasta
    Product/Service revenue
    4590000000
  3. Product/Service/Dept. name
    Aranesp
    Product/Service revenue
    1800000000

Innovation assets and Pipeline

Investment into R&D:
$3840000000 USD
Total patents held:
1349
Number of patents field last year:
22

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the pharmaceuticals sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations.
*However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on health services to support them in their greying years.
*The economic strain of this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs that may improve the overall physical and mental health of seniors, so that they remain well enough to lead independent lives outside the care of hospitals and nursing homes.
*By the early 2030s, a range of treatments will emerge to stunt and later reverse the effects of aging. These treatments will be provided annually and over time will become affordable to the masses, resulting in longer average human lifespans and a new windfall for the pharmaceutical industry.
*By 2050, the world population will rise above nine billion, over 80 percent of whom will live in cities. The high numbers and density of the future human population will result in more regular pandemic outbreaks that spread faster and are harder to cure.
*The eventual widespread adoption of artificial intelligence (AI) and quantum computing within the pharmaceutical industry will lead to new, AI-assisted discoveries of drugs and treatments to cure a range of medical conditions. These AI pharmaceutical researchers will also result in new drugs and treatments being discovered at a far faster rate than is currently possible.

COMPANY’S FUTURE PROSPECTS

Company Headlines